Follow-up of SARS-CoV-2 positive subgroup from the Asymptomatic novel CORonavirus iNFection study.


Journal

Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876

Informations de publication

Date de publication:
05 2021
Historique:
revised: 12 01 2021
received: 30 11 2020
accepted: 15 01 2021
pubmed: 20 1 2021
medline: 4 5 2021
entrez: 19 1 2021
Statut: ppublish

Résumé

A nested longitudinal study within theAsymptomatic novel CORonavirus iNFfection study followed participants with positive nasopharyngeal swab to query for development of symptoms and assess duration of positive reverse transcription-polymerase chain reaction (RT-PCR) test results. Of the 91 participants initially testing positive, 86 participated in follow-up approximately 14 days after study enrollment; of those 86 participants, 19 (22.1%) developed at least one symptom at any time after the initial positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result. The median number of days to symptom development after their initial positive test result was 6 (range 1-29 days). No participants reported a SARS-CoV-2-related hospitalization. The most frequently reported symptoms were fatigue or muscle aches (10.5%), headache (9.3%), fever (5.8%), and shortness of breath (5.8%). Of the 78 participants who submitted a nasopharyngeal swab for repeat RT-PCR testing, 17 (21.8%) remained positive at Day 14, 4 of which continued to test positive at Day 28. These findings reinforce the probable role of silent SARS-CoV-2 infections in community transmission, and that reliance on symptom development will miss a large proportion of infections. Broad testing programs not limited to individuals presenting with symptoms are critical for identifying persons with SARS-CoV-2 infection and ultimately slowing transmission.

Identifiants

pubmed: 33463731
doi: 10.1002/jmv.26810
pmc: PMC8014630
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2925-2931

Subventions

Organisme : Eli Lilly and Company

Informations de copyright

© 2021 The Authors. Journal of Medical Virology Published by Wiley Periodicals LLC.

Références

J Med Virol. 2021 May;93(5):2925-2931
pubmed: 33463731
JAMA Netw Open. 2021 Jan 4;4(1):e2035057
pubmed: 33410879
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Euro Surveill. 2022 Feb;27(8):
pubmed: 35209972
J Med Virol. 2020 Nov;92(11):2874-2879
pubmed: 32543722
J Clin Med. 2020 Apr 24;9(4):
pubmed: 32344679
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
MMWR Morb Mortal Wkly Rep. 2020 Jun 12;69(23):714-721
pubmed: 32525850
Clin Epidemiol. 2020 Oct 08;12:1039-1043
pubmed: 33116898
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930

Auteurs

Kristin J Meyers (KJ)

Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.

Brian Dillman (B)

Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.

Charles Williams (C)

Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.

Jianfei Jiang (J)

Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.

Nancy Clifford (N)

Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.

Jennifer L Miller (JL)

Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.

Meghan E Jones (ME)

Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.

Iris A Goetz (IA)

Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.

Fady T Botros (FT)

Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.

Jack Knorr (J)

Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.

David H Manner (DH)

Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.

Brad Woodward (B)

Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH